Acceleron Pharma (XLRN) Tops Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Join SI Premium – FREE
Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.32), $0.17 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $5.72 million versus the consensus estimate of $4.23 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Traws Pharma (TRAW) Tops Q2 EPS by 27c
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
